MORE controversy about using pioglitazone (Actos, etc) for type 2 diabetes

New concerns about bladder cancer mean you'll hear MORE controversy about using pioglitazone (Actos, etc) for type 2 diabetes.

Pioglitazone is off the market in France while authorities investigate. Regulators in other countries are also assessing its risks.

We're advising pharmacists and prescribers to keep the risk of bladder cancer in perspective.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote